[1] |
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest, 2011, 121(7):2750-2767.
|
[2] |
Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell, 2019,35(3):428-440.
|
[3] |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172.
|
[4] |
Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline[J]. J Clin Oncol,2021, 39(13):1485-1505.
|
[5] |
National Comprehensive Cancer Network. Clinical practice guidelines in oncology, breast cancer (NCCN guidelines version 1.2022) [M]. Fort Washington, PA: National Comprehensive Cancer Network, 2022.
|
[6] |
中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2022[M].北京:人民卫生出版社,2022.
|
[7] |
中国抗癌协会乳腺癌专业委员会.乳腺癌诊治指南与规范(2022版)[M].北京:人民卫生出版社,2022.
|
[8] |
《中国乳腺癌新辅助治疗专家共识(2022年版)》专家组. 中国乳腺癌新辅助治疗专家共识(2022年版)[J]. 中国癌症杂志,2022,32(1):80-89.
|
[9] |
National Comprehensive Cancer Network. Clinical practice guidelines in oncology, breast cancer (NCCN guidelines version 2.2023) [M]. Fort Washington, PA: National Comprehensive Cancer Network, 2023.
|
[10] |
Fasching PA, Link T, Hauke J, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)[J]. Ann Oncol, 2021, 32(1): 49-57.
|
[11] |
Carey LA, Winer EP. I-SPY 2—toward more rapid progress in breast cancer treatment[J]. N Engl J Med, 2016, 375(1): 83-84.
|
[12] |
Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis[J]. Am J Physiol, 1996, 270(4 Pt 2): F700-F708.
|
[13] |
Eguchi Y, Shimizu S, Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis[J]. Cancer Res, 1997, 57(10): 1835-1840.
|
[14] |
Zhou R, Vander Heiden MG, Rudin CM. Genotoxic exposure is associated with alterations in glucose uptake and metabolism[J]. Cancer Res, 2002, 62(12): 3515-3520.
|
[15] |
Hirsch T, Marchetti P, Susin S A, et al. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death[J]. Oncogene, 1997, 15(13): 1573-1581.
|
[16] |
Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, et al. AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells[J]. J Cell Mol Med, 2009, 13(9b): 3644-3654.
|
[17] |
Alba E, Chacon JI, Lluch A, et al. A randomized phase Ⅱ trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study[J]. Breast Cancer Res Treat, 2012, 136: 487-493.
|
[18] |
von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial[J]. Lancet Oncol, 2014, 15: 747-756.
|
[19] |
Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance)[J]. J Clin Oncol, 2015, 33: 13-21.
|
[20] |
Wu X, Tang P, Li S, et al. A randomized and open-label phase Ⅱ trial reports the efficacy of neoadjuvant lobaplatin in breast cancer[J]. Nat Commun, 2018, 9(1): 832.
|
[21] |
Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19: 497-509.
|
[22] |
Poggio F, Bruzzone M, Ceppi M et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis[J]. Ann Oncol, 2018, 29: 1497-1508.
|
[23] |
Gupta S, Nair NS, Hawaldar R, et al. Abstract GS5-01: Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: a phase Ⅲ randomized controlled trial[J].Cancer Res,2023, 83 (5_Supplement): GS5-01.
|
[24] |
Zhu T, Liu C, Zhang Y, et al. A phase Ⅱ trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer[J]. Breast Cancer Res Treat, 2016, 156: 117-124.
|
[25] |
Sharma P, López-Tarruella S, García-Saenz JA, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts[J]. Clin Cancer Res, 2017, 23: 649-657.
|
[26] |
Zhang P, Yin Y, Mo H, et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial[J]. Oncotarget, 2016, 7(37): 60647-60656.
|
[27] |
Sharma P, Kimler BF, O’dea A, et al. Randomized phase Ⅱ trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage Ⅰ-Ⅲ triple-negative breast cancer (NeoSTOP)[J]. Clin Cancer Res, 2021, 27: 975-982.
|
[28] |
Zhang L, Wu Z Y, Li J, et al. Neoadjuvant docetaxel plus carboplatin versus epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label phase Ⅱ trial[J]. Int J Cancer, 2022, 150(4): 654-662.
|
[29] |
Gluz O, Nitz U, Liedtke C, et al. Comparison of neoadjuvant nab-paclitaxel+ carboplatin vs nab-paclitaxel+ gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results[J]. J Natl Cancer Inst, 2018, 110(6): 628-637.
|
[30] |
Geyer CE, Sikov WM, Huober J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase Ⅲ trial[J]. Ann Oncol, 2022, 33(4): 384-394.
|
[31] |
Loibl S, Weber KE, Timms KM, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto[J]. Ann Oncol, 2018, 29: 2341-2347.
|
[32] |
Shepherd JH, Ballman K, Polley MYC, et al. CALGB 40603 (alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer[J]. J Clin Oncol, 2022, 40(12): 1323-1334.
|
[33] |
Yan W, Wu X, Wang S, et al. Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase Ⅱ trial[J]. Ther Adv Med Oncol, 2022, 14: 1-10.
|
[34] |
Zhao F, Shen G, Dong Q, et al. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis[J]. Clin Exp Med, 2022: 1-16.
|
[35] |
Poggio F, Tagliamento M, Ceppi M, et al. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate[J]. Ann Oncol, 2022, 33(3): 347-349.
|
[36] |
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer[J]. N Engl J Med, 2020, 382(9): 810-821.
|
[37] |
Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer[J]. N Engl J Med, 2022, 386(6): 556-567.
|
[38] |
Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study[J]. Ann Oncol, 2022, 33(5): 534-543.
|
[39] |
Sharma P, Stecklein S, Yoder R, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial[J]. JAMA Oncol, 2023 Nov 22:e235033. doi: 10.1001/jamaoncol.2023.5033
|
[40] |
Du F, Wang W, Wang Y, et al. Carboplatin plus taxanes are noninferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple -negative breast cancer[J]. Breast Cancer Res Treat, 2020, 182(1): 67-77.
|
[41] |
Yu KD, Ye FG, He M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(9): 1390.
|
[42] |
Mayer IA, Zhao F, Arteaga CL, et al. Randomized phase Ⅲ postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131[J]. J Clin Oncol, 2021, 39(23): 2539-2551.
|
[43] |
Shin DS, Chahwan C, Huffman JL, et al. Structure and function of the double-strand break repair machinery[J]. DNA Repair, 2004, 3(8-9): 863-873.
|
[44] |
Koboldt DC, Fulton RS, McLellan MD, et al. Comprehensive molecular portraits of human breast tumours[J]. Nature, 2012, 490(7418): 61-70.
|
[45] |
Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing[J]. Breast Cancer Res Treat, 2014, 145: 707-714.
|
[46] |
Jeong HM, Kim RN, Kwon MJ, et al. Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients[J]. Oncotarget, 2017, 8(37): 61538.
|
[47] |
Jia X, Wang K, Xu L, et al. A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer[J]. Breast, 2022, 66: 31-39.
|
[48] |
Telli ML, Jensen KC, Vinayak S, et al. Phase Ⅱ study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutationassociated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105[J]. J Clin Oncol, 2015, 33(17): 1895-1901.
|
[49] |
Hahnen E, Lederer B, Hauke J, et al. germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: Secondary analysis of the geparsixto randomized clinical trial[J]. JAMA Oncol, 2017, 3(10): 1378-1385.
|
[50] |
Tung N, Arun B, Hacker M R, et al. TBCRC 031: Randomized phase Ⅱ study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial)[J]. J Clin Oncol, 2020, 38(14): 1539-1548.
|
[51] |
Mayer EL, Abramson V, Jankowitz R, et al. TBCRC 030: a phase Ⅱ study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.[J].Ann Oncol, 2020, 31(11): 1518-1525.
|
[52] |
Zhang L, Wu Z, Li J, et al. Impact of homologous recombination deficiency on outcomes in patients with triple-negative breast cancer treated with carboplatin-based neoadjuvant chemotherapy: secondary analysis of the NeoCART randomized clinical trial[J]. JCO Precis Oncol, 2023, 7: e2200337.
|
[53] |
Zhang L, Chen Y, Cheng MY, et al. Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis[J]. Ther Adv Med Oncol, 2022, 14:17588359221096253.
|
[54] |
康一坤,袁芃.《铂类药物晚期乳腺癌应用专家共识(2020版)》解读[J].中国肿瘤临床,2022,49(6):271-274.
|
[55] |
陈煜. 铂类抗肿瘤药物不良反应及防治措施[J].临床合理用药杂志,2019,12(28):120-122.
|
[56] |
铂类药物临床应用与不良反应管理专家共识[J].今日药学,2019,29(9):577-585.
|
[57] |
李莉,王友群,孙蔚莉,等.含铂方案治疗晚期乳腺癌临床研究[J].中华肿瘤防治杂志,2016,23(10):657-662.
|
[58] |
Loibl S, Untch M, Burchardi N, et al. A randomised phase Ⅱ study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study[J]. Ann Oncol, 2019, 30(8): 1279-1288.
|
[59] |
Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial[J]. Lancet, 2020, 396(10257): 1090-1100.
|